Beneficial effects of perhexiline in cardiovascular disease states / Yuliy Y. Chirkov, Aaron L. Sverdlov, and John D. Horowitz Chirkov, Yuliy Y

User activity

Send to:
View the summary of this work
Author
Chirkov, Yuliy Y
Subjects
Perhexiline - Therapeutic use.; Angina pectoris - Chemotherapy.; Cardiovascular agents.
Summary
Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline's reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease. http://trove.nla.gov.au/work/37252295 Yuliy Y. Chirkov, Aaron L. Sverdlov, and John D. Horowitz
Bookmark
http://trove.nla.gov.au/work/37252295
Work ID
37252295

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this work

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this work

Add a comment


Show comments and reviews from Amazon users